Synapse Open Synapse
Biology

Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial

Nature Medicine · · 35 min read

In a nonrandomized phase 2 trial, patients with resectable non-small cell lung cancer received perioperative ivonescimab as monotherapy or with chemotherapy, leading to encouraging pathological response rates in both cohorts, and sustained circulating tumor DNA negativity throughout neoadjuvant therapy may be predictive of response.

Latest from Nature Medicine